Background Robotic total pancreatectomy (TP) represents a minimally invasive approach to a major intra-abdominal operation. Its utility, technique, and outcomes are evolving. Methods In this video, we describe a systematic approach to a robotic total pancreatectomy performed for multifocal intraductal papillary mucinous neoplasm (IPMN). Additionally, we reviewed the National Cancer Database (NCDB) to examine the outcomes of robotic TP compared to laparoscopic and open TP between 2010 and 2014. Results The patient is a 61-year-old female who was diagnosed with multifocal IPMN. A total of 6 robotic ports were placed and the da Vinci Xi robotic system was used with the patient supine. The approach entailed as follows: (1) 
Total pancreatectomy (TP) is indicated for the treatment of pancreatic cancer when most of the pancreas is involved, for multifocal pathologies involving the entire gland, such as intraductal papillary mucinous neoplasm (IPMN), or uncommonly in refractory chronic pancreatitis. Its benefits have to be weighed carefully against its significant morbidity, which is the highest among pancreatectomies [1] [2] [3] [4] .
Robotic-assisted pancreatic surgery is increasingly being utilized. Most reports come from a few experienced centers [5] [6] [7] . The operative technique is evolving and the short-and long-term outcomes are unknown. Herein, we describe our technique with a robotic-assisted total pancreatectomy for multifocal branch duct IPMN involving the entire pancreas. Additionally, we reviewed the National Cancer Database (NCDB) to examine the nationwide utilization and outcomes of robotic total and Other Interventional Techniques Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00464-017-6003-1) contains supplementary material, which is available to authorized users.
pancreatectomy. In order to assess the long-term oncologic outcome of robotic total pancreatectomy, we examined the survival of patients diagnosed with adenocarcinoma of the pancreas.
Methods
The NCDB is a hospital-based cancer registry sponsored by a joint program between the American College of Surgeons Commission on Cancer (CoC) and the American Cancer Society [8] . It represents approximately 70% of all newly diagnosed cancer cases nationwide from more than 1500 hospitals. The surgical approach (open, robotic, laparoscopic) is available for the period 2010-2014. The Pancreatic Participant Use Data File (PUF) is a Health Insurance Portability and Accountability Act (HIPAA)-compliant data file containing deidentified data.
Institutional review board approval was not required for this study because no patient identifiers were examined.
For the purpose of this study, we included operations of primary site codes 40: total pancreatectomy and 60: total pancreatectomy and subtotal gastrectomy or duodenectomy. The postoperative outcomes of robotic TP were compared to laparoscopic TP and open TP. Robotic and laparoscopic operations categorized as converted to open were examined with the open TP.
The survival of patients diagnosed with adenocarcinoma utilizing the histology codes 8140 for adenocarcinoma and 8500 for ductal carcinoma was examined. We elected to limit the survival analysis to pancreatic adenocarcinoma patients as these represented the majority (73%) of patients who underwent a robotic total pancreatectomy. Patients with histology codes 8453, intraductal papillary mucinous carcinoma and 8480, mucinous adenocarcinoma represented only 8% of the patients who underwent a robotic total pancreatectomy.
Continuous variables are presented as median and range or mean and standard deviation. Categorical variables are presented as proportions. We assessed group differences using Fisher's exact or Pearson x 2 test for categorical variables. Continuous variables were compared with the student's t test when the distribution was normal, or the Wilcoxon rank-sum test and Kruskal-Wallis test when the distribution was not normal. Survival curves were constructed with the Kaplan-Meier method and differences assessed with the log rank test. Statistical analysis was performed using SPSS Statistics v23 software (IBM Corp, Armonk, NY).
Results

Surgical technique (video)
A 61-year-old female with multifocal branch duct IPMN involving the entire pancreas was evaluated. She was a type 1 diabetic on an insulin pump with a history of robotic total abdominal hysterectomy for stage 1 endometrial cancer. Fine needle aspiration of a complex cyst located at the pancreas neck was significant for a CEA of 2080; however, the pancreatic cysts did not harbor "high risk stigmata" [9] , therefore the option of expectant management was discussed with her and she elected to proceed with a robotic total pancreatectomy to minimize her risk of developing pancreatic cancer. The patient was positioned supine. We utilized the 30°, 8-mm Endoscope, 6 robotic ports, and the da Vinci Xi robotic system. We proceeded in the following stepwise fashion:
(1) Diagnostic laparoscopy We did not identify any evidence of suspicious extrapancreatic disease or other pathologies. (2) Entry into the lessec sac The gastrocolic ligament was divided and the anterior surface of the body and tail of the pancreas was exposed. The patient was discharged home on postoperative day 9 after an uneventful postoperative course. She returned bowel function on postoperative day 5 after which she was transitioned to oral pain medications and advanced to a diabetic diet. The rest of her hospitalization was related to optimization of her glycemic management. Final pathology consisted with multifocal branch duct IPMN without evidence of invasive cancer and 0/26 nodes negative for cancer.
National cancer database data
Clinicopathologic characteristics
During the period 2010-2014, we identified 3876 patients who underwent total pancreatectomy (TP) with/without subtotal gastrectomy or duodenectomy of which 73 (1.9%) were robotic assisted, 455 (11.7%) laparoscopic, and 3348 (86.4%) open.
The 73 patients who underwent a robotic TP represent the focus of this study. The utilization of robotic TP tripled during the study period from 8 cases in 2010 to 24 in 2014. Table 1 illustrates the clinicopathologic data of this cohort. Intraductal papillary mucinous carcinoma and mucinous adenocarcinoma patients represented only 8% of the robotic total pancreatectomies cohort, whereas the majority (73%) suffered from pancreatic ductal adenocarcinoma. The median age of the patients was similar between robotic, laparoscopic, and open TP, most patients were Caucasian with a Charlson index 0, and underwent TP at an academic research program.
Postoperative results
Overall, the percentage of margin negative resections was similar between robotic, laparoscopic, and open TP (89.6 vs. 89.8 vs. 85.9%, respectively; p = 0.14). The median number of lymph nodes retrieved was similar (14 vs. 14 vs. 15, respectively; p = 0.06). The median duration of in-hospital stay was improved for robotic and laparoscopic TP compared to open TP (8 vs. 7 vs. 9 days, respectively; p < 0.001). Readmission rates were similar with a trend for lower readmission rates for robotic and laparoscopic TP versus open TP (6.8 vs. 7.2 vs. 9.6%, respectively; p = 0.2), whereas 30-and 90-day mortality rates were improved with robotic and laparoscopic TP versus open TP (30 days: 2 vs. 1.2 vs. 4.8%, respectively; p = 0.006 and 90 days: 4.3 vs. 5 vs. 9.4%, respectively; p = 0.02). The association of robotic TP with decreased mortality was significant even after multivariate logistic regression analysis (Table 2 ).
Long-term survival for pancreatic ductal adenocarcinoma
The long-term survival of patients with pancreatic ductal adenocarcinoma was examined. This was the most common indication for robotic TP (72.6%). The median overall survival was similar between robotic, laparoscopic, and open TP performed for pancreatic adenocarcinoma (22.5 vs. 22.4 vs. 20.2 months, respectively, p = 0.22; Fig. 1 ).
Discussion
In this report, we describe a stepwise approach to robotic total pancreatectomy (TP), and we provide nationwide data on its utilization, short-and long-term outcomes. Evaluation of the NCDB on TP cases, revealed that the use of robotic TP was associated with decreased hospital stay and postoperative mortality at 30 and 90 days compared to open TP and similar to laparoscopic TP. Its oncologic outcome was equivalent to laparoscopic and open TP with similar rates of margin negative resections and retrieved lymph nodes. Additionally, the median overall survival after TP for pancreatic ductal adenocarcinoma was comparable between the three approaches.
In our video, we performed a robotic TP for multifocal branch duct IPMN. The majority of robotic TPs in the NCDB cohort were performed for pancreatic adenocarcinoma. Total pancreatectomy is considered for tumors involving the entire pancreas such as pancreatic cancer or main duct IPMN, for multifocal tumors, i.e., branch duct IPMN, neuroendocrine tumors, or metastases, i.e., from renal cell cancer, for history of familial pancreatic cancer and presence of multifocal PanIN, or for patients with chronic pancreatitis and intractable pain with possible islet cell autotransplantation [1, 6] . From a technical perspective, the application of robotic technology did not alter the course of total pancreatectomy in our case, but it conferred benefits associated with the use of the robotic platform. These include the superior visualization (increased magnification, 3-dimensional view, improved depth of perception), such as during the creation of the retropancreatic/portal vein tunnel, and the ergonomical advantages (seven ranges of motion vs. the four of laparoscopy, tremor filtration, articulating instruments), and render the robot beneficial for precise surgical dissection and fine suturing, for example, during the bilioenteric anastomosis in our video. The benefits of robotic technology during total pancreatectomy have been emphasized in existing small case series [6, 10] . When robotic TP is performed for islet cell autotransplantation, the blood supply to the pancreas is preserved until the very end of the operation to maximize the islet yield [11] . We did not need to perform a vascular resection in our case; however, the feasibility of robotic-assisted vascular resections during pancreatic surgery has been demonstrated therefore the utilization of robotic surgery should not be precluded on the basis of vascular resection necessity [12] . However, robotic surgery is not without hazards. Injury to major structures such as the portal vein can result in operative mortality [13, 14] . It is imperative that major resections are being performed in centers with experience and the procedure should be converted when there are safety concerns.
With appropriate experience, robotic pancreatic surgery can be performed with acceptable morbidity [7] . In our report, robotic and laparoscopic TP were associated with shorter hospital stay and improved 30-and 90-day mortality compared to open TP. We similarly have shown improved postoperative outcome and shortened hospital stay for minimally invasive distal pancreatectomies with frail patients deriving the greatest benefit [15] . Boggi et al. in a casematched study of 11 robotic versus open equal TP found lower blood loss with the robotic TP and similar postoperative morbidity [16] . Zureikat et al. in a multi-institutional comparison of robotic versus open pancreaticoduodenectomy found reduced blood loss and major complications with the robotic approach [17] . Finally, Liu et al. [18] in a retrospective study comparing 27 robotic-assisted to 25 laparoscopic pancreaticoduodenectomies found reduced blood loss, and shorter hospital stay associated with the robotic-assisted group. Larger studies are needed before definite conclusions can be made. It is also equally important to realize that robotic-assisted pancreatic surgery is associated with a significant learning curve with improvement in operative results (conversions to open surgery, estimated blood loss, operative time) and readmission rates after the first 20-40 cases [19, 20] .
In this study, analysis of NCDB data from 3876 patients that had undergone TP demonstrated oncologic equivalence between robotic, laparoscopic, and open TP, with similar rates of margin negative resections and retrieved lymph nodes. Additionally, the median overall survival when TP was performed for pancreatic adenocarcinoma was similar between the three approaches. The application of minimally invasive pancreatic surgery is associated with equivalent oncologic outcomes to open surgery with regard to the completion of resection and extent of lymphadenectomy [17] .
Conclusion
In conclusion, we describe and illustrate with an accompanying video a stepwise approach to a robotic total pancreatectomy performed for a multifocal IPMN. NCDB data support that the utilization of robotic TP has tripled from 2010 to 2014 and is associated, similarly to laparoscopic TP, with decreased hospitalization and postoperative mortality compared to open TP. Its long-term oncologic outcome appears equivalent to laparoscopic and open TP when performed for pancreatic adenocarcinoma.
